Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Non-Current Assets (2017 - 2025)

Acro Biomedical has reported Non-Current Assets over the past 9 years, most recently at $13651.0 for Q2 2025.

  • Quarterly results put Non-Current Assets at $13651.0 for Q2 2025, down 69.22% from a year ago — trailing twelve months through Dec 2025 was $33975.0 (down 78.75% YoY), and the annual figure for FY2024 was $26898.0, down 52.67%.
  • Non-Current Assets for Q2 2025 was $13651.0 at Acro Biomedical, down from $20324.0 in the prior quarter.
  • Over the last five years, Non-Current Assets for ACBM hit a ceiling of $56833.0 in Q4 2023 and a floor of $6268.0 in Q3 2021.
  • Median Non-Current Assets over the past 5 years was $28423.5 (2022), compared with a mean of $29931.8.
  • Biggest five-year swings in Non-Current Assets: tumbled 82.07% in 2021 and later surged 481.9% in 2024.
  • Acro Biomedical's Non-Current Assets stood at $54662.0 in 2021, then crashed by 45.21% to $29949.0 in 2022, then surged by 89.77% to $56833.0 in 2023, then crashed by 52.67% to $26898.0 in 2024, then tumbled by 49.25% to $13651.0 in 2025.
  • The last three reported values for Non-Current Assets were $13651.0 (Q2 2025), $20324.0 (Q1 2025), and $26898.0 (Q4 2024) per Business Quant data.